- Time:
Membrane proteins are key targets for therapeutic intervention using antibody biologics. Over 60% of FDA-approved drugs act on these proteins. Studying them is challenging because the proteins must be embedded in lipid bilayers to retain their native structure. Many membrane proteins also require post-translational modifications, such as glycosylation, to function properly. Current technologies for studying membrane proteins either involve expression in cell-based systems, which can lead to high background from contaminating endogenous proteins, or purification using detergents or nanodiscs, both of which can result in receptor inactivation.
In this GEN webinar, our speaker, Eric Johansen, PhD, will demonstrate the utility of virion-displayed membrane proteins for screening antibody biologics. He will present the VirD membrane protein array technology, which displays membrane proteins in the membrane envelope of herpes simplex virus-1 (HSV-1) virions. The technology is designed for high-throughput biochemical analysis of membrane proteins. Membrane protein expression occurs during virus replication, ensuring that the integrated proteins undergo endogenous folding and post-translational modifications in their native and active conformations. He will also share the results of testing various commercial and clinical antibodies.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
R&D Applications Scientist
CDI Laboratories
Webinar produced with support from:
